Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003832 · ClinicalTrials.gov registry record · Phase 2
Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00003832: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00003832 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003832, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE conventional surgery
- DRUG bromodeoxyuridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1999-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003832
The ClinicalTrials.gov registry entry for NCT00003832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00003832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003832 about?
NCT00003832 is a clinical study titled "Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer". Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment
What is the current status of trial NCT00003832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 1999-07.
What interventions are being tested in trial NCT00003832?
The interventions under investigation include: laboratory biomarker analysis (OTHER), conventional surgery (PROCEDURE), bromodeoxyuridine (DRUG).
Who is sponsoring clinical trial NCT00003832?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.